SDGR icon

Schrodinger

21.43 USD
-1.41
6.17%
At close Jun 13, 4:00 PM EDT
After hours
21.35
-0.08
0.37%
1 day
-6.17%
5 days
-14.25%
1 month
-9.81%
3 months
-2.28%
6 months
2.88%
Year to date
5.05%
1 year
0.99%
5 years
-68.21%
10 years
-25.17%
 

About: Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Employees: 787

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

206% more call options, than puts

Call options by funds: $15.3M | Put options by funds: $5M

33% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 24

15% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 65

9% more capital invested

Capital invested by funds: $1.19B [Q4 2024] → $1.3B (+$112M) [Q1 2025]

6.28% more ownership

Funds ownership: 97.19% [Q4 2024] → 103.47% (+6.28%) [Q1 2025]

2% more funds holding

Funds holding: 210 [Q4 2024] → 215 (+5) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$32
49%
upside
Avg. target
$32
49%
upside
High target
$32
49%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Keybanc
Scott Schoenhaus
49%upside
$32
Overweight
Maintained
16 Apr 2025

Financial journalist opinion

Based on 42 articles about SDGR published over the past 30 days

Positive
Seeking Alpha
1 day ago
Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results
Schrödinger's SGR-1505 Phase 1 data shows encouraging safety and niche efficacy, especially in BTKi-resistant Waldenström macroglobulinemia patients. Despite a headline 22% ORR, the nuanced data supports continued development, though competition and high efficacy benchmarks in B-cell malignancies remain challenges. Financially, Schrödinger's software business is growing steadily, with strong cash reserves and manageable risks, supporting ongoing R&D investment.
Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results
Neutral
Accesswire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Neutral
PRNewsWire
3 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. ("Schrödinger" or the "Company") (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Neutral
Business Wire
3 days ago
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress
MILAN--(BUSINESS WIRE)--Schrödinger announces encouraging initial clinical data from its ongoing Phase 1 dose-escalation study of SGR-1505.
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress
Neutral
Accesswire
4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Neutral
GlobeNewsWire
5 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Neutral
Accesswire
5 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Neutral
PRNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. ("Schrödinger" or the "Company") (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Neutral
GlobeNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASDAQ:SDGR). Investors who purchased Schrödinger securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SDGR.
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation
Charts implemented using Lightweight Charts™